Stock Report

All about this stock under one free report Last Updated: 29-Aug-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

This month’s issue could change how you invest, read now.

Recently Viewed

Clear All

Lincoln Pharma Key Ratios

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: LINCOLN | BSE: 531633

₹614.95

up-down-arrow ₹0.95 (0.15%)

As on 28-Aug-2026IST

Market cap

info icon

₹1,233 Cr

Revenue (TTM)

info icon

₹694 Cr

P/E Ratio

info icon

12.8

P/B Ratio

info icon

1.6

Div. Yield

info icon

0.3 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -5.34 15.07 10.19 9.94 9.42
EBIT 11.22 15.84 -3.37 1.20 0.87
Net Profit 211.45 30.93 11.70 7.84 8.32
EPS 211.42 30.93 11.70 7.84 8.31
Book Value -- -- 13.30 15.77 16.46
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMMar-25Mar-24
EBIT-Margin info 15.0916.5112.4514.2215.38
Net Margin info 13.8714.1013.0912.7515.17
Return on equity info 15.2216.2713.0913.0217.04
Return on Capital info 20.6322.22--17.5522.53
Return on Assets info 12.1012.6811.4310.6413.70
Debt to Equity (x) info ----0.000.000.00

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
17.55
22.53
21.82
24.29
Peer Median
--
21.76
21.89
--
17.36
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

13.09

Lower than Peers by 2.26

Profit after tax / Average Net worth * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
13.09
13.02
17.04
15.59
17.35
Peer Median
15.35
17.93
16.42
--
17.35
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

11.43

Higher than Peers by 1.08

Profit after tax / Average Total assets * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
11.43
10.64
13.70
12.24
13.31
Peer Median
10.35
12.81
12.32
--
10.65
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

12.45

Lower than Peers by 5.56

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
12.45
14.22
15.38
15.68
18.51
Peer Median
18.01
18.93
21.05
--
11.27
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

13.09

Lower than Peers by 1.36

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
13.09
12.75
15.17
13.68
14.39
Peer Median
14.45
14.94
15.51
--
11.45
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

--

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
14.59
17.12
15.35
15.60
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

10.19

Lower than Peers by 1.75

Year on year growth in net sales

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
10.19
7.35
13.76
8.09
11.30
Peer Median
11.95
10.90
13.44
--
11.49
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-3.37

Lower than Peers by 24.97

Year on year growth in operating profit (EBIT)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
-3.37
-0.77
11.55
-8.42
9.76
Peer Median
21.60
15.01
23.50
--
-1.10
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

11.70

Lower than Peers by 11.03

Year on year growth in profit after tax

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
11.70
-11.74
27.99
5.11
11.41
Peer Median
22.73
14.80
30.12
--
4.90
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

11.70

Lower than Peers by 8.33

Year on year growth in earnings per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
11.70
-11.75
27.99
5.11
11.41
Peer Median
20.03
14.27
29.02
--
10.00
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

--

--

Year on year growth in book value per share

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
13.30
17.98
16.08
18.15
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
--
0.00
0.00
0.00
Peer Median
0.00
0.06
0.03
--
0.18
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

--

--

(Short term borrowings / Net worth)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
--
0.00
0.00
0.00
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

5.25

Higher than Peers by 3.17

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
5.25
4.00
3.94
4.07
3.37
Peer Median
2.08
1.90
2.23
--
1.72
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

4.53

Higher than Peers by 2.99

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
4.53
3.40
3.29
3.34
2.71
Peer Median
1.54
1.46
1.59
--
1.41
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

121.33

Higher than Peers by 101.95

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
121.33
58.99
84.45
50.50
67.11
Peer Median
19.38
24.96
45.29
--
24.64
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

23.26

Higher than Peers by 1.87

Debtors outstanding / Net Sales * 100

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
23.26
26.70
27.86
26.72
24.56
Peer Median
21.38
21.77
20.10
--
23.77
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.82

Higher than Peers by 0.10

Sales / Average Total Assets

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
0.82
0.84
0.89
0.90
0.95
Peer Median
0.72
0.76
0.81
--
1.05
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
91.75
89.63
86.09
84.27
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
43.57
44.26
48.72
43.86
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
141.73
110.27
124.63
138.44
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
--
-6.41
23.61
10.19
-10.30
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

12.78

Lower than Peers by 21.20

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
12.78
13.42
12.57
9.31
8.98
Peer Median
33.99
26.81
39.85
--
26.65
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

1.55

Lower than Peers by 3.51

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
1.55
1.64
1.98
1.35
1.44
Peer Median
5.06
4.65
6.11
--
3.55
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

0.29

Lower than Peers by 0.20

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
0.29
0.33
0.31
0.44
0.48
Peer Median
0.49
0.61
0.37
--
0.04
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

8.38

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
8.38
8.73
8.63
5.79
5.75
Peer Median
--
27.02
34.57
--
17.31
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

1,233

Lower than Peers by 17,892

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Mar-25
Mar-24
Mar-23
Mar-22
Lincoln Pharma
1,233
1,105
1,173
678
623
Peer Median
19,125
20,914
25,297
--
474
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...